Top in endocrinology: ADA guideline updates, metformin recall

The American Diabetes Association recently issued its 2022 Standards of Care, which includes recommendations for screening and first-line therapy. It was the top story in Endocrinology last week.

Another top story was about a voluntary safety recall of metformin products. Viona Pharmaceuticals, Inc., announced that it withdrew 33 lots of metformin hydrochloride tablets due to the presence of N-Nitrosodimethylamine, or NDMA.

Read these and more top stories in endocrinology below:

First-line therapy, diabetes screening updates among changes in ADA 2022 Standards of Care

Recommendations for first-line therapy and comorbidities, diabetes screening in adults and gestational diabetes testing are among the changes in the American Diabetes Association’s 2022 Standards of Care. Read more.

Voluntary safety recall of contaminated metformin products

Viona Pharmaceuticals, Inc., is voluntarily recalling 33 lots of metformin hydrochloride extended-release tablets, USP 750 mg, due to presence of NDMA, according to a company statement. Read more.

Facts about diabetes and COVID-19 vaccination

Susan Weiner, MS, RDN, CDCES, FADCES, talks with Stephen W. Ponder, MD, FAAP, CDCES, about the effects of COVID-19 infection and vaccination for people with diabetes. Read more.

Abnormal thyroid hormones during pregnancy linked to behavioral problems in boys

Abnormal thyroid hormone levels during pregnancy are associated with an increased risk for behavioral problems in preschool-aged boys, but not girls, according to study data published in The Journal of Clinical Endocrinology & Metabolism. Read more.

Weight loss from bariatric surgery cuts COVID-19 complications risks

Substantial weight loss after bariatric surgery was associated with improved COVID-19 outcomes compared with nonsurgical controls, including a 49% lower risk for hospitalization and a 60% lower risk for developing severe disease, data show. Read more.